The décolletage has long been an underserved area in aesthetic medicine, often neglected while the face receives the majority of attention and innovation. As patient demand for comprehensive, full-body rejuvenation continues to grow—a trend highlighted in our recent aesthetic medicine updates—the chest has emerged as a priority treatment zone for “body skin quality.”
The recent FDA approval of RADIESSE for the treatment of wrinkles in the décolleté area in patients 22 years of age and older marks a meaningful shift, bringing new regulatory clarity to this delicate region. This article explores the anatomy of the décolletage, distinguishes it from the neck, and provides a comprehensive breakdown of the latest injectable and non-injectable treatments available to practitioners in 2026.
What you will learn in this article:
Before exploring treatment options, it is essential to understand the unique anatomy of the décolletage and how it differs from the neck. The décolletage is generally defined as the upper chest area—specifically the triangular region extending from the lower neck down to the upper breast, bounded laterally by the shoulders.
The skin in this region is structurally distinct from facial skin. It possesses a thinner dermis, fewer sebaceous glands, and a lower concentration of melanocytes, making it particularly vulnerable to photoaging, environmental damage, and decreased capacity for self-repair. Furthermore, the chest is highly susceptible to “sleep wrinkles”—creases that form due to side-sleeping and gravitational pull—which can become permanent over time as collagen and elastin diminish.
A common point of patient confusion is the distinction between chest wrinkles and platysma bands. These are anatomically and clinically different problems requiring entirely different treatment approaches.
Platysma bands are vertical cords that appear on the anterior neck, caused by the weakening and separation of the platysma muscle—a broad, thin muscle extending from the upper chest to the jawline. As the overlying skin thins with age, these muscle bands become more prominent, particularly during facial expressions or neck movement. The standard treatment for platysma bands is the injection of neuromodulators (such as Botox or Dysport) to relax the muscle—a technique covered extensively in comprehensive Botox training programs.
In contrast, décolletage wrinkles are primarily horizontal or diagonal creases on the chest skin itself, resulting from collagen loss, photoaging, and mechanical folding from sleep position. Because chest rhytides are driven by skin laxity and volume loss rather than muscle overactivity, they respond better to fillers, biostimulators, and resurfacing—not standard neuromodulator dosing.
In April 2026, Merz Aesthetics received FDA approval for RADIESSE for the treatment of wrinkles in the décolleté area in patients 22 years of age and older. This new indication makes RADIESSE the first and only regenerative biostimulator in the U.S. approved for both face and body (hands and décolleté).
RADIESSE is composed of 30% synthetic calcium hydroxylapatite (CaHA) microspheres suspended in a 70% carrier gel. When injected into the décolletage, it provides immediate structural support while simultaneously stimulating the body’s natural production of collagen and elastin over time. Clinical trial data demonstrated that over 80% of patients were satisfied with skin tightness, and 90% of healthcare providers reported visible improvements at four months.
For the décolletage indication, RADIESSE is typically administered in a diluted or hyperdilute formulation—mixed with saline and lidocaine—to allow for even distribution across the chest using a cannula technique.
Practitioners must be aware of one specific and important safety consideration: the CaHA microspheres in RADIESSE are radiopaque, meaning they are visible on X-rays and CT scans. At the FDA’s August 2025 advisory panel meeting, experts raised the theoretical concern that filler material in the décolleté could interfere with mammograms, produce false-positive findings on breast imaging, or affect lymphatic drainage.
A 75-patient study found that diluted RADIESSE injections in the décolleté were not visible on mammograms or breast ultrasounds in that cohort. However, the FDA has required a post-approval study to further characterize radiographic visibility across imaging modalities. Until that data is available, practitioners have a clear duty of care: patients must be fully counseled on this characteristic and instructed to disclose their RADIESSE injections to any physician or radiologist prior to breast imaging.
Patients who are pregnant or breastfeeding, or who have a history of breast cancer, lymphoma, prior chest radiotherapy, or impaired wound healing may warrant additional caution and more extensive shared decision-making, particularly in light of limited long-term imaging data for this new indication.
RADIESSE is currently the only FDA-approved injectable specifically indicated for wrinkles in the décolleté area. Several other injectables are used off-label on the chest by experienced practitioners; careful patient selection and informed consent are essential when considering any off-label use. Providers should ensure they have completed rigorous aesthetic provider certification before attempting advanced off-label body injections.
While SKINVIVE by Juvéderm is currently FDA-approved for improving skin smoothness of the cheeks, it has become a staple off-label treatment for the décolletage. As a micro‑droplet intradermal HA, it is designed to improve skin hydration and smoothness without the ‘puffy’ look of traditional fillers. It is often the preferred U.S. alternative for patients seeking “Profhilo-like” results for chest crepiness and dullness. In June 2025, AbbVie announced the FDA accepted an sPMA for SKINVIVE for the improvement of neck appearance, indicating its growing profile in non-facial applications.
Sculptra (poly-L-lactic acid, PLLA) is FDA-approved for specific facial indications but is used off-label for body rejuvenation, including the décolletage. Unlike RADIESSE, Sculptra provides no immediate volumizing effect. It functions as a pure biostimulator, working gradually over several months to stimulate deep collagen synthesis and improve skin thickness and quality. A 2017 study using a five-point chest wrinkle scale demonstrated measurable improvement in rhytides and skin texture following off-label PLLA treatment of the chest.
Most protocols use two to three sessions spaced four to six weeks apart, with results developing over three to six months and lasting up to two years. For the décolletage, Sculptra is reconstituted with a higher volume of sterile water than for facial use, and injected using a cannula in a fanning or cross-hatching pattern to ensure even distribution.
HArmonyCa (Allergan Aesthetics) is a next-generation hybrid filler that uniquely blends crosslinked hyaluronic acid (HA) and calcium hydroxylapatite (CaHA). While widely used in Europe and other international markets, it is not FDA‑approved or commercially available in the United States as of early 2026. When used off-label for the chest in authorized markets, it provides the dual benefit of immediate HA-driven hydration and lifting, alongside long-term CaHA-driven collagen biostimulation in a single step.
Profhilo is not FDA-approved in the United States as of early 2026; all neck and décolletage use occurs in markets where the product is authorized and remains an off-label, protocol-driven application. In Europe and the UK, it is positioned as a high-concentration HA “bioremodeler” that spreads evenly beneath the skin to stimulate collagen, elastin, and adipogenesis. Similarly, polynucleotide (PN) injectables (e.g., Nucleofill) are gaining traction internationally for chest “biorevitalization” but remain not FDA-approved in the U.S.
For patients who are not candidates for injectables, or who require comprehensive skin resurfacing, a range of energy-based devices and procedural options offer meaningful results. Increasingly, 2026 protocols use combination ‘hybrid’ therapy—priming the skin with IPL or lasers to clear pigmentation, then adding biostimulation (RADIESSE or Sculptra) about four weeks later to address laxity.
IPL is well-established as the primary treatment for the photoaging changes most commonly seen on the décolletage: pigmented lesions, telangiectasias, and poikiloderma of Civatte. It uses polychromatic, non-coherent light to target melanin and hemoglobin chromophores, with results for pigmentation lasting up to four years following a series of three to four treatments spaced four weeks apart. IPL does not meaningfully address skin laxity or deep rhytides, and is contraindicated in Fitzpatrick skin types V–VI due to the risk of hypopigmentation.
Both ablative (e.g., fractional CO2) and non-ablative fractional lasers are effective for resurfacing the chest, addressing moderate to severe rhytides, skin texture, and collagen stimulation. Cartessa Aesthetics’ Helix laser — a combination CO2 and non-ablative 1570nm device — has been specifically highlighted by practitioners for use on the décolleté, arms, and hands, offering simultaneous resurfacing, sun damage correction, and superficial collagen contraction in a single pass.
A critical technical consideration across all fractional modalities: chest skin heals more slowly than facial skin and has a lower density of adnexal structures from which re-epithelialization occurs. Practitioners must use conservative fluence settings and longer recovery intervals compared to facial protocols to minimize the risk of scarring or post-inflammatory hyperpigmentation.
RF microneedling devices combine the mechanical collagen induction of microneedling with the thermal remodeling effect of radiofrequency energy delivered deep into the dermis and subdermal tissue. This dual-mechanism approach is particularly well-suited to the décolletage, where skin laxity and crepiness are the primary concerns.
Platforms such as VirtueRF by Cartessa Aesthetics — which features a Deep handpiece specifically designed for body skin tightening — and Scarlet SRF by Viol, developed by Viol Co., Ltd. (South Korea) and distributed in the U.S. by Aesthetic Management Partners, which is FDA‑cleared for dermatologic use and is marketed for treatment of the face, neck, décolletage, and body, are among the options practitioners are deploying for chest rejuvenation alongside established platforms such as Morpheus8 and Potenza.
Chest treatments with Ultherapy and similar MFU‑V devices are off‑label and should follow conservative energy settings.
A major shift in 2026 protocols is the addition of topical exosomes immediately following energy-based treatments. Because chest skin has fewer adnexal structures and heals more slowly than the face, some clinics are experimenting with topical growth factor and exosome‑containing products immediately after energy‑based treatments. These products are not FDA‑approved for aesthetic use, and their application in this context is entirely off‑label, with limited high‑quality data. Patients should be counseled accordingly, and providers must follow evolving FDA and state guidance.
Regulatory status and clinical parameters reflect U.S. practice as of 2026. Off-label use requires informed consent; individual patient factors and device settings will vary.
| Treatment | Primary Indication | Regulatory Status | Downtime | Duration of Results |
|---|---|---|---|---|
| FDA Approved RADIESSE (CaHA) Calcium hydroxylapatite biostimulator; diluted or hyperdilute cannula technique. | Wrinkles & skin laxity | FDA approved for décolleté wrinkles (April 2026); also approved for hands and face | Minimal (bruising possible) | Up to 2 years |
| SKINVIVE by Juvéderm (HA) Micro‑droplet intradermal HA for hydration and smoothness. | Hydration, crepiness & skin smoothness | FDA approved for cheeks; off-label for chest | 24–48 hours | Up to 6 months |
| Sculptra (PLLA) Pure biostimulator; gradual collagen synthesis over 3–6 months. | Global volumization & skin thickness | FDA approved for facial indications; off-label for chest | Minimal | Up to 2 years |
| HArmonyCa (Hybrid HA + CaHA) Immediate HA lift + long-term CaHA biostimulation in a single injection. | Laxity, volume & biostimulation | Not FDA‑approved or available in the U.S. as of 2026; authorized in some international markets. Décolletage use follows local, often off‑label, protocols. | Minimal | 12–18 months (estimated) |
| Intense Pulsed Light (IPL) Targets melanin and hemoglobin; contraindicated in Fitzpatrick V–VI. | Pigmentation, telangiectasias & poikiloderma of Civatte | FDA cleared for skin rejuvenation; commonly used on chest | < 3 days | Up to 4 years (pigment) |
| Fractional Laser (CO2 / Non-ablative) Conservative settings required; slower healing than face. Helix (Cartessa) combines CO2 + 1570nm. | Rhytides, skin texture & collagen stimulation | FDA cleared for skin resurfacing; widely used for neck and chest when permitted by device indication. | 7–14 days (ablative); 2–5 days (non-ablative) | Long-lasting with maintenance |
| RF Microneedling VirtueRF (Cartessa), Scarlet SRF (Viol / AMP), Morpheus8, Potenza. | Skin laxity, crepiness & texture | FDA cleared for dermatologic uses; commonly applied to face, neck, décolletage and body per device‑specific protocols. | 2–5 days | 12–18 months |
| HIFU (e.g., Ultherapy) Focused ultrasound to mid-dermis and SMAS; results develop over 3–6 months. | Skin tightening & lifting | FDA cleared for face and neck; chest use is off-label | Minimal | 12–18 months |
| Topical Exosomes Applied post-energy treatment to reduce downtime and accelerate collagen signaling. | Post-procedure healing & collagen support | Not FDA‑approved for aesthetic use; use as a topical adjunct after procedures is experimental/off‑label and should comply with evolving FDA and state guidance. | N/A (adjunctive) | Adjunctive — enhances primary treatment outcomes |
* Regulatory status reflects U.S. FDA designations as of April 2026. Off-label use of any product requires appropriate patient counseling, informed consent, and clinical judgment. Duration of results is approximate and will vary based on patient age, skin quality, treatment protocol, and number of sessions.
How long do the results of RADIESSE last in the décolletage?
Clinical data indicates that results can last up to two years, although many patients maintain visible improvement for approximately 12 to 18 months depending on age, skin quality, and their specific treatment plan.
Are all chest injectables FDA-approved for the décolletage?
No. RADIESSE is currently the only injectable with an FDA indication specifically for wrinkles in the décolleté area. Sculptra, SKINVIVE, and techniques such as intradermal “micro-Botox” on the chest are all off-label applications that should be performed only by experienced injectors with appropriate patient counseling and consent.
Can neuromodulators be used for décolletage wrinkles?
Neuromodulators are the appropriate treatment for platysma bands on the anterior neck, not for chest wrinkles. Some practitioners use intradermal “micro-Botox” techniques off-label for very superficial chest lines, but this approach does not address volume loss or deep rhytides and carries a risk of unwanted muscle weakening. Fillers, biostimulators, and energy-based devices are generally the preferred approach for décolletage rejuvenation.
What laser settings are appropriate for the chest?
The chest requires more conservative settings than the face across all laser modalities. The dermis is thinner, adnexal density is lower, and healing is slower — all of which increase the risk of scarring and post-inflammatory hyperpigmentation if standard facial parameters are applied. Practitioners should reduce fluence, increase pass intervals, and counsel patients on extended recovery timelines.
Should RADIESSE patients notify their radiologist before a mammogram?
Yes. Because CaHA microspheres are radiopaque, patients who have received RADIESSE in the décolletage should inform their physician and radiologist prior to any breast imaging. The FDA has required Merz to conduct a post-approval study to further characterize the visibility of RADIESSE on various imaging modalities.
Botox® vs. Dysport®, key technique insights, and 9 expert recommendations to help you avoid common mistakes as a new cosmetic injector.
References:
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!